340318-88-9

Basic information

• Product Name: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine
• Synonyms: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine
• CAS NO: 340318-88-9
• Molecular Formula: C₁₆H₂₀N₂O
• Molecular Weight: 256.3428
• Mol File: 340318-88-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 423.4±45.0 °C(Predicted)
• Appearance: /
• Density: 1.10±0.1 g/cm3(Predicted)
• PKA: 3.63±0.40(Predicted)
• CAS DataBase Reference: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine(340318-88-9)
• EPA Substance Registry System: 4-[4-(2,5-dimethyl-1H-pyrrol-1-yl)phenyl]morpholine(340318-88-9)

Safety Data

• Hazardous Substances Data: 340318-88-9(Hazardous Substances Data)

Upstream product

• 10389-51-2 1-morpholino-4-nitrobenzene 
• 110-13-4 2,5-hexanedione 
• 2524-67-6 4-morpholino-4-yl-phenylamine 

Downstream Products

• 347324-32-7 2,5-dimethyl-1-(4-(4-morpholinyl)phenyl)-1H-pyrrole-3-carbaldehyde 
• 1428183-65-6 C₂₅H₂₉N₃O₄ 

Relevant articles and documents

A New FXR Ligand Chemotype with Agonist/Antagonist Switch

Therapeutic modulation of the bile acid-sensing transcription factor farnesoid X receptor (FXR) is an appealing strategy to counteract hepatic and metabolic diseases. Despite the availability of several highly potent FXR agonists structural diversity of FXR modulators is limited, and new ligand scaffolds are needed. Here we report structure-activity relationship elucidation of a new FXR modulator chemotype whose activity can be tuned between agonism and antagonism by two minor structural modifications. Starting from a weak FXR/PPAR agonist, we have developed selective FXR activators and antagonists with nanomolar to low-micromolar potencies and binding affinities. The new FXR ligand chemotype modulates the FXR activity in the native cellular setting, is endowed with favorable metabolic stability, and lacks cytotoxicity. It valuably expands the collection of FXR modulators as a new scaffold for FXR-targeted drug discovery.

Discovery and optimisation studies of antimalarial phenotypic hits

There is an urgent need for the development of new antimalarial compounds. As a result of a phenotypic screen, several compounds with potent activity against the parasite Plasmodium falciparum were identified. Characterization of these compounds is discussed, along with approaches to optimise the physicochemical properties. The in vitro antimalarial activity of these compounds against P. falciparum K1 had EC50 values in the range of 0.09e29 mM, and generally good selectivity (typically >100-fold) compared to a mammalian cell line (L6). One example showed no significant activity against a rodent model of malaria, and more work is needed to optimise these compounds.